Compumedics Limited researches, develops, manufactures, sells, and distributes medical devices in Australia, the Asia Pacific, the Americas, Europe, and the Middle East.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.39|
|52 Week High||AU$0.35|
|52 Week Low||AU$0.58|
|1 Month Change||2.63%|
|3 Month Change||1.30%|
|1 Year Change||-11.36%|
|3 Year Change||5.41%|
|5 Year Change||-49.35%|
|Change since IPO||-56.18%|
Recent News & Updates
Compumedics (ASX:CMP) Will Want To Turn Around Its Return Trends
What are the early trends we should look for to identify a stock that could multiply in value over the long term...
Here's Why Compumedics (ASX:CMP) Has A Meaningful Debt Burden
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Returns On Capital Signal Tricky Times Ahead For Compumedics (ASX:CMP)
To find a multi-bagger stock, what are the underlying trends we should look for in a business? Ideally, a business will...
|CMP||AU Medical Equipment||AU Market|
Return vs Industry: CMP underperformed the Australian Medical Equipment industry which returned -8.2% over the past year.
Return vs Market: CMP underperformed the Australian Market which returned 21.4% over the past year.
Stable Share Price: CMP is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: CMP's weekly volatility (9%) has been stable over the past year.
About the Company
Compumedics Limited researches, develops, manufactures, sells, and distributes medical devices in Australia, the Asia Pacific, the Americas, Europe, and the Middle East. It provides sleep diagnostics products, including Grael 4K PSG:EEG amplifiers; Somté PSG; Siesta 802, an ambulatory recording device; Grael PSG; and Somté, an investigative tool. The company also provides neurology diagnostics, such as ONsight A.V.S. for monitoring patient's home ambulatory studies; Grael 4K PSG:EEG amplifiers; Grael 4K-EEG amplifiers; Grael LT EEG System amplifiers; Neuvo 64-512 Channel LTM EEG monitoring systems; Xegis Forte EMG/EP; and Xegis G:NEO 2 Channel EMG/EP systems.
Compumedics Fundamentals Summary
|CMP fundamental statistics|
Is CMP overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CMP income statement (TTM)|
|Cost of Revenue||AU$16.58m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||0.0056|
|Net Profit Margin||2.79%|
How did CMP perform over the long term?See historical performance and comparison
Is Compumedics undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate CMP's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate CMP's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: CMP is poor value based on its PE Ratio (69.3x) compared to the Australian Medical Equipment industry average (13.7x).
PE vs Market: CMP is poor value based on its PE Ratio (69.3x) compared to the Australian market (19.8x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CMP's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CMP is good value based on its PB Ratio (3.1x) compared to the AU Medical Equipment industry average (4.6x).
How is Compumedics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Compumedics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Compumedics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CMP has a large one-off gain of A$955.0K impacting its June 30 2021 financial results.
Growing Profit Margin: CMP became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: CMP's earnings have declined by 37.5% per year over the past 5 years.
Accelerating Growth: CMP has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: CMP has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (74.9%).
Return on Equity
High ROE: CMP's Return on Equity (4.5%) is considered low.
How is Compumedics's financial position?
Financial Position Analysis
Short Term Liabilities: CMP's short term assets (A$31.9M) exceed its short term liabilities (A$15.4M).
Long Term Liabilities: CMP's short term assets (A$31.9M) exceed its long term liabilities (A$1.0M).
Debt to Equity History and Analysis
Debt Level: CMP's debt to equity ratio (22.5%) is considered satisfactory.
Reducing Debt: CMP's debt to equity ratio has increased from 17.4% to 22.5% over the past 5 years.
Debt Coverage: CMP's debt is well covered by operating cash flow (26.5%).
Interest Coverage: CMP's interest payments on its debt are not well covered by EBIT (2.9x coverage).
What is Compumedics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CMP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CMP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CMP's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CMP's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CMP's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
David Burton (62 yo)
Dr. David Burton, Ph.D. founded Compumedics Ltd. in 1987 and serves as its Executive Chairman and Chief Executive Officer. Dr. Burton serves as Executive Chairman and Chief Executive Officer of Compumedics...
CEO Compensation Analysis
Compensation vs Market: Insufficient data to establish whether David's total compensation is reasonable compared to companies of similar size in the Australian market.
Compensation vs Earnings: David's compensation has been consistent with company performance over the past year.
Experienced Board: CMP's board of directors are considered experienced (4.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Compumedics Limited's employee growth, exchange listings and data sources
- Name: Compumedics Limited
- Ticker: CMP
- Exchange: ASX
- Founded: 1987
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: AU$69.094m
- Shares outstanding: 177.16m
- Website: https://www.compumedics.com.au
- Compumedics Limited
- 30-40 Flockhart Street
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/22 07:03|
|End of Day Share Price||2021/10/21 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.